Polymyositis and dermatomyositis laboratory findings: Difference between revisions
Line 42: | Line 42: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Percentage | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Percentage | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti-Jo-1 | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Histidyl-tRNA synthetase | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Antisynthetase syndrome | * Antisynthetase syndrome | ||
Line 50: | Line 50: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti Mi-2) | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Chromodomain helicase DNA binding protein 4 | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Severe dermatomyositis rash without significant lung involvement | * Severe dermatomyositis rash without significant lung involvement | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti-SRP | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Signal recognition particle | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Flare up in fall | * Flare up in fall | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti PL-12 | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Alanyl-tRNA synthetase | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Epstein-Barr virus (EBV), adenovirus, and influenza infection | * Epstein-Barr virus (EBV), adenovirus, and influenza infection | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti TIF-1γ antibody | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Transcriptional intermediary factor 1-gamma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
Line 75: | Line 75: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti NXP-2 antibody | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Nuclear matrix protein | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
Line 82: | Line 82: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + |Anti | | align="left" style="background:#F5F5F5;" + |Anti-SAE antibody | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |Anti-small ubiquitin-like modifier activating enzyme | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| align="left" style="background:#F5F5F5;" + |Anti | | align="left" style="background:#F5F5F5;" + |Anti HMGCR antibody | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + |3-hydroxy-3-methylglutaryl-coenzyme A reductase | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Statin-associated necrotizing autoimmune myopathy (SANAM) | * Statin-associated necrotizing autoimmune myopathy (SANAM) |
Revision as of 16:30, 12 April 2018
Polymyositis and dermatomyositis Microchapters |
Differentiating Polymyositis and dermatomyositis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Polymyositis and dermatomyositis laboratory findings On the Web |
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
Polymyositis and dermatomyositis laboratory findings in the news |
Blogs on Polymyositis and dermatomyositis laboratory findings |
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Different laboratory tests may be used to diagnose polymyositis and dermatomyositis and exclude other myopathies which include:[1][2]
- Sarcoplasmic enzymes
- Myositis-specific autoantibodies
Sarcoplasmic enzymes
- Sarcoplasmic enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:[3]
- Creatine phosphokinase
- Aldolase
- Transaminases
- Lactic dehydrogenase
Myositis-specific autoantibodies
Autoantibody | Antigen | Association | Percentage |
---|---|---|---|
Anti-Jo-1 | Histidyl-tRNA synthetase |
|
|
Anti Mi-2) | Chromodomain helicase DNA binding protein 4 |
|
|
Anti-SRP | Signal recognition particle |
|
|
Anti PL-12 | Alanyl-tRNA synthetase |
|
|
Anti TIF-1γ antibody | Transcriptional intermediary factor 1-gamma |
|
|
Anti NXP-2 antibody | Nuclear matrix protein |
|
|
Anti-SAE antibody | Anti-small ubiquitin-like modifier activating enzyme |
|
|
Anti HMGCR antibody | 3-hydroxy-3-methylglutaryl-coenzyme A reductase |
|
6% |
References
- ↑ Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
- ↑ Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.
- ↑ Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.